Inactive Instrument

Theradiag

ALTER

FR0004197747

Theradiag SA Provides Earnings Guidance for the Full Year 2020

September 21, 2020 at 11:45 am EDT

Theradiag SA provided earnings guidance for the full year 2020. For the year, the company indicated likely impact of around 10% on revenue.

Latest news about Theradiag

Biosynex: merger with Theradiag completed	Dec. 18	CF
Theradiag SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-21	CI
Theradiag: improved first-half profitability	23-09-18	CF
Theradiag: 7% growth in half-year sales	23-07-17	CF
Theradiag SA Reports Audited Revenue Results for the Second Quarter and First Half Ended on June 30, 2023	23-07-17	CI
Theradiag SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-26	CI
Theradiag SA Announces Executive Changes	23-03-01	CI
Theradiag SA Announces Management Changes	23-03-01	CI
Biosynex SA completed the acquisition of additional 46.52% stake in Theradiag SA for €21.6 million.	23-01-30	CI
Biosynex: takeover bid reopened for Theradiag shares	23-01-18	CF
Theradiag: takeover bid reopened on January 18	23-01-17	CF
Theradiag: 2022 sales without surprises	23-01-16	CF
Biosynex: successful takeover bid for Theradiag	23-01-16	CF
Theradiag: over 2.8 million shares tendered to the takeover bid	23-01-16	CF
Theradiag: growth of nearly 10% in 2022	23-01-16	CF
Theradiag SA Announces Revenue Results for the Year Ended December 31, 2022	23-01-16	CI
Biosynex SA completed the acquisition of 40% stakes in Theradiag SA.	23-01-11	CI
French Diagnostics Company Biosynex Offers to Take Over Theradiag	22-09-23	MT
Biosynex SA bid to acquire remaining 74.93% stakes in Theradiag SA.	22-09-22	CI
Theradiag SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-19	CI
Theradiag SA Announces Revenue Results for the Six Months Ended June 30, 2022	22-07-18	CI
Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics	22-06-08	CI
Theradiag Announces the Launch of ez-Track, A Point-Of-Care Testing Solution for Therapeutic Drug Monitoring	22-05-31	CI
THERADIAG Announces the Launch of Two New i-Tracker® Kits	22-05-19	CI
Theradiag Announces Executive Changes	22-05-06	CI

Theradiag develops, produces, and sells in vitro diagnostic kits for detecting auto-immune diseases, allergies, and infectious diseases. The group also offers theranostic tests for monitoring biotherapies and determining patient response to treatments applied. 54.6% of net sales are abroad.

Sector

More about the company

Theradiag

Equities

ALTER

FR0004197747

Theradiag SA Provides Earnings Guidance for the Full Year 2020

Latest news about Theradiag

Chart Theradiag

Company Profile